AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON (Reuters) - AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

More U.S. babies dying of suffocation, often in bed

(Reuters Health) - The number of babies dying of suffocation before their first birthday has been rising in recent years, driven at least in part by an increase in the number of parents sharing beds with their infants, a U.S. study suggests.

Serious knee injuries increasing in kids and teens

(Reuters Health) - Injuries to a critical ligament in the knee are becoming more common in children and teens, researchers warn.

Malawi cholera cases pass 500, eight people dead

BLANTYRE (Reuters) - Cholera cases in Malawi have tripled and four more people have died, the Ministry of Health said on Monday, a month after the spread of the disease from Zambia was thought to have been contained.

Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

(Reuters) - A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

(Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell.

Preemies and underweight babies more likely to have low IQs

(Reuters Health) - Babies who are born much too soon or who arrive weighing too little may not score as high on intelligence tests during childhood as full-term infants, a research review suggests.

New acne diagnoses linked to increased depression risk

(Reuters Health) - In the first year after being told by a doctor that they have acne, patients’ risk for a diagnosis of major depressive disorder spikes by more than 60 percent compared to the general population, a new study shows.

Novartis readies to auction U.S. generic pills business: sources

(Reuters) - Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

U.S. faces shortage of developmental and behavioral pediatrics specialists

(Reuters Health) - A shortage of clinicians specializing in pediatric behavioral and developmental disorders is translating into long wait times for new patient appointments amid surging demand, a new study suggests.

Related Videos

Using seawater and crisp packets to cut CO2 emissions

University of York scientists say 850 million tonnes of carbon dioxide could be mineralised each year by combining sea water, graphite, solar-powered electricity, and scrap metal in a purpose-built reactor. Jim Drury reports.

Catalyst makes alcohol and perfume from air

A US start-up has developed a catalyst and reactor that turns air, sunlight and water into pure ethanol for use in consumer products like alcoholic spirits and perfume. Stuart McDill reports.
Read Reuters on the go

Download the free Reuters News app today for breaking news, analysis and market data from the world's most trusted news organization.

Get the app